HK1257730A1 - 抗despr單克隆抗體用於癌症和中風的靶向療法及成像 - Google Patents
抗despr單克隆抗體用於癌症和中風的靶向療法及成像Info
- Publication number
- HK1257730A1 HK1257730A1 HK19100103.3A HK19100103A HK1257730A1 HK 1257730 A1 HK1257730 A1 HK 1257730A1 HK 19100103 A HK19100103 A HK 19100103A HK 1257730 A1 HK1257730 A1 HK 1257730A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- stroke
- imaging
- monoclonal antibody
- targeted therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562208937P | 2015-08-24 | 2015-08-24 | |
PCT/US2016/048427 WO2017035249A1 (en) | 2015-08-24 | 2016-08-24 | ANTI-DEspR MONOCLONAL ANTIBODY TARGETED THERAPY AND IMAGING FOR CANCER AND STROKE |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1257730A1 true HK1257730A1 (zh) | 2019-10-25 |
Family
ID=58101030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK19100103.3A HK1257730A1 (zh) | 2015-08-24 | 2019-01-03 | 抗despr單克隆抗體用於癌症和中風的靶向療法及成像 |
Country Status (6)
Country | Link |
---|---|
US (2) | US10202457B2 (zh) |
EP (1) | EP3341413A4 (zh) |
AU (2) | AU2016311265B2 (zh) |
CA (1) | CA2995716A1 (zh) |
HK (1) | HK1257730A1 (zh) |
WO (1) | WO2017035249A1 (zh) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013538191A (ja) | 2010-07-23 | 2013-10-10 | トラスティーズ オブ ボストン ユニバーシティ | 病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗DEsupR阻害剤 |
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
EP3341413A4 (en) | 2015-08-24 | 2019-07-17 | Trustees of Boston University | MONOCLONAL ANTI-DESPR ANTIBODY-TARGETED TREATMENT AND IMAGING FOR CANCER AND AVC |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
EP3684400A4 (en) * | 2017-09-18 | 2021-06-16 | Trustees of Boston University | METHOD OF TREATMENT OF NETOSE AND NEUTROPHILER ACTIVATION |
BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
US10953107B2 (en) | 2018-06-15 | 2021-03-23 | Trustees Of Boston University | Polypeptide compositions and methods for site-specific targeting of therapeutic agents |
JP2022552786A (ja) * | 2019-10-09 | 2022-12-20 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 標的化epha3及びその使用 |
US11584792B2 (en) * | 2020-10-15 | 2023-02-21 | Trustees Of Boston University | Antibody therapies and methods for treating coronavirus infection |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US5969098A (en) | 1997-06-06 | 1999-10-19 | Cyberchemics, Inc. | Yeast-toxin-related protein for antimicrobial vaccine and sterilizing preservative use |
US7504490B1 (en) * | 1998-10-16 | 2009-03-17 | Oscient Pharmaceuticals Corporation | Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics |
CA2452058A1 (en) | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
EP2194144B1 (en) | 2004-11-16 | 2015-01-07 | Trustees of Boston University | Anti-Dual Endothelin-1/Angiotensin II receptor (DEAR) antibody for inhibiting disease-associated or pathological angiogenesis. |
EP1988167B1 (fr) | 2005-02-17 | 2020-04-01 | Sorbonne Universite | Peptides inhibiteurs intracellulaires |
US20090317836A1 (en) | 2006-01-30 | 2009-12-24 | The Scripps Research Institute | Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject |
JP2009060790A (ja) | 2006-03-01 | 2009-03-26 | Suntory Ltd | 酵母に乾燥耐性および/または低温保存耐性を付与する活性を有するタンパク質をコードする遺伝子及びその用途 |
EP2318040A4 (en) | 2008-07-24 | 2013-05-01 | Univ Central Florida Res Found | THERAPY TREATED ON CANCER STAMPS |
ES2811342T3 (es) | 2009-03-31 | 2021-03-11 | Ligand Pharm Inc | Antagonista de receptores de endotelina y angiotensina II de bifenilsulfonamida para tratar glomeruloesclerosis y nefropatía inducida por IgA |
JP2013538191A (ja) | 2010-07-23 | 2013-10-10 | トラスティーズ オブ ボストン ユニバーシティ | 病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗DEsupR阻害剤 |
US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
WO2015051152A1 (en) | 2013-10-03 | 2015-04-09 | Leuvas Therapeutics | Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease |
WO2016127255A1 (en) | 2015-02-10 | 2016-08-18 | Palaniyar Nadesalingam | Mediation of inflammatory response using inhibitors of netosis |
EP3341413A4 (en) | 2015-08-24 | 2019-07-17 | Trustees of Boston University | MONOCLONAL ANTI-DESPR ANTIBODY-TARGETED TREATMENT AND IMAGING FOR CANCER AND AVC |
-
2016
- 2016-08-24 EP EP16840046.3A patent/EP3341413A4/en active Pending
- 2016-08-24 US US15/245,853 patent/US10202457B2/en active Active
- 2016-08-24 AU AU2016311265A patent/AU2016311265B2/en active Active
- 2016-08-24 CA CA2995716A patent/CA2995716A1/en active Pending
- 2016-08-24 WO PCT/US2016/048427 patent/WO2017035249A1/en unknown
-
2019
- 2019-01-03 HK HK19100103.3A patent/HK1257730A1/zh unknown
- 2019-01-31 US US16/263,202 patent/US11236169B2/en active Active
-
2023
- 2023-04-20 AU AU2023202436A patent/AU2023202436A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016311265B2 (en) | 2023-03-16 |
US20190153106A1 (en) | 2019-05-23 |
AU2016311265A1 (en) | 2018-03-08 |
WO2017035249A1 (en) | 2017-03-02 |
CA2995716A1 (en) | 2017-03-02 |
US10202457B2 (en) | 2019-02-12 |
EP3341413A1 (en) | 2018-07-04 |
US20170058036A1 (en) | 2017-03-02 |
EP3341413A4 (en) | 2019-07-17 |
AU2023202436A1 (en) | 2023-06-29 |
US11236169B2 (en) | 2022-02-01 |
AU2016311265A9 (en) | 2023-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257730A1 (zh) | 抗despr單克隆抗體用於癌症和中風的靶向療法及成像 | |
HK1245134A1 (zh) | 用抗lap單克隆抗體治療癌症 | |
ZA202001285B (en) | Antigen-binding proteins targeting shared antigens | |
IL275547A (en) | Antigen-binding proteins target co-antigens | |
HK1252272A1 (zh) | 使用抗ox40抗體治療癌症的方法 | |
DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
EP3377102C0 (en) | ANTI-PD-1 ANTIBODIES AND THEIR THERAPEUTIC USES | |
HUE048939T2 (hu) | Human B sejt érési antigén elleni monoklonális antitestek (BCMA) | |
IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
IL277861A (en) | Axl-specific antibodies for cancer treatment | |
ZA202000851B (en) | Antibodies useful in cancer diagnosis | |
SG11201707949XA (en) | Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy | |
IL268460A (en) | Treatment of bladder cancer with an antibody against pd-l1 | |
HK1243434A1 (zh) | Igf-1r抗體及其診斷癌症的用途 | |
SG11201703292VA (en) | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | |
IL280421A (en) | Cancer treatment by antibody | |
HK1248730A1 (zh) | Igf-1r抗體及其用於癌症診斷的用途 | |
DK3344287T3 (da) | Anti-survivin-antistoffer til cancerterapi | |
GB201813138D0 (en) | Cancer treatment with an antibody | |
GB201509493D0 (en) | Therapeutic antibody |